The anti-inflammatory effects of ketamine: State of the art

Acta Anaesthesiologica Belgica

Volumn 62, Issue 1, 2011, Pages 47-58

  Loix, Sébastien ^a   De Kock, Marc ^b   Henin, Pierre ^a  

^a Hospital de Jolimont   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cytokin; Inflammation; Ketamine

Indexed keywords

CYCLOOXYGENASE 2; ETOMIDATE; FENTANYL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KETAMINE; MIDAZOLAM; NITRIC OXIDE; PROSTAGLANDIN E2; SODIUM CHLORIDE; THIOPENTAL; TUMOR NECROSIS FACTOR ALPHA;

ANESTHESIA INDUCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CYTOKINE PRODUCTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; REVIEW; VAGUS NERVE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; KETAMINE; NEUROSECRETORY SYSTEMS; NITRIC OXIDE; VAGUS NERVE;

EID: 79957571097     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Selye H., Forty years of stress research : principal remaining problems and misconceptions, CAN. MED. Assoc. J., 115, 53-56, 1976.
2. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., Panoskaltsis N., Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412, NEJM, 355, 1018-1028, 2006.
3. Lippman M., Appel P. L., Mok M. S., Shoemaker W. C., Sequential cardiorespiratory patterns of anesthetic induction with ketamine in critically ill, CRIT. CARE MED., 11 (9), 730-734, 1983.
4. Longnecker D. E., Sturgill B. C., Influence of anesthetic agents on survival following hemorrhage, ANESTHESIOLOGY, 45 (5), 516-21, 1976.
5. Lankveld D. P. K., Bull S., Van Dijk P., Fink-Gremmels J., Hellebrekers L. J., Ketamine inhibits LPS-induced tnf-alpha and interleukin-6 in an equine macrophage cell line, VET. RES., 36, 257-262, 2005.
6. Li C. Y., Chou T. C., Wong C. S., Ho S. T., Wu C. C., Yen M. H., Ding Y. A., Ketamine inhibits nitric oxide synthase in lipopolysaccharide-treated rat alverolar macrophages, CAN. J. ANESTH., 44 (9), 989-995, 1997.
7. Shimaoka M., Iida T., Ohara A., Taenaka N., Mashimo T., Honda T., Yoshiva I., Ketamine inhibits nitric oxide production in mouse-activated macrophage-like cells, BR. J. ANESTH., 77, 238-242, 1996.
8. Chang Y., Chen T. L., Sheu J. R., Chen R. M., Suppressive effects of ketamine on macrophage functions, Tox. APPL. PHARMACOL., 204 (1), 27-35, 2005.
9. Yang J., Li W., Duan M., Zhou Z., Lin N., Wang Z., Sun J., Xu J., Large dose ketamine inhibits lipopolysaccharid-induced acute lung injury in rats, INFLAMM. RES., 54, 133-137, 2005.
10. Pekoe G. M., Peden D., Van Dyke K., Impairement of leukocyte myeloperoidase bactericidal mechanisms with ketamine, AGENTS AND ACTIONS, 13 (1), 59-62, 1983.
11. Takenaka I., Ogata M., Koga K., Matsumoto T., Shigematsu A., Ketamine suppresses endotoxin-induced tumor necrosis factor alpha production in mices, ANESTHESIOLOGY, 80, 402-408, 1994.
12. Zilberstein G., Levy R., Rachinsky M., Fisher A., Greemberg L., Shapira Y., Appelbaum A., Roytblat L., Ketamine attenuates neutrophil activation after cardiopulmonary bypass, ANEST. ANALG., 95, 531-6, 2002.
13. Krumholz W., Endrass J., Hempelmann G., Inhibition of phagocytosis and killing of bacteria by anaesthetic agents in vitro, BRIT. J. ANAESTH., 75, 66-70, 1995.
14. Zahler S., Heindl B., Becker B. F., Ketamine does not inhibit inflammatory responses of cultured human endothelial cells but reduces chemotactic activation of neutrophils, ACTA ANAESTHESIOL. SCAND., 43,1011-1016, 1999.
15. Hofbauer R., Moser D., Hammerschmidt V., Kapiolis S., Frass M., Ketamine significantly reduces the migration of leukocytes through endothelial cell monolayers, CRIT. CARE MED., 26 (9), 1545-1549, 1998.
16. Schmidt H., Ebeling D., Bauer H., Bach A., Bohrer H., Gebhard M., Martin E., Ketamine attenuates endotoxin-induced leukocyte adherence in rat mesenteric venules, CRIT. CARE MED., 23 (12) ; 2008-2014,1995.
17. Weigand M. A., Schmidt H., Zhao' Q., Plaschke K., Martin E., Bardenheuer H. J., Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro, ANESTH. ANALG., 90, 206-212, 2000.
18. Nakagawa T., Hirakata H., Sato M., Nakamura K., Hatano Y., Nakamura T., Ketamine suppresses platelet aggregation possibly by suppressed inositol triphosphate formation and subsequent suppression of cytosolic calcium increase, ANESTHESIOLOGY, 96, 1147-52, 2002.
19. Undar A., Eichstaedt H. C., Clubb F. J., Lu M., Bigley J. E., Deady B. A., Porter A., Vaughn W. K., Fung M., Anesthetic induction with ketamine inhibits platelet activation before, during and after cardiopulmonary bypass in baboons, ARTIF. ORGANS, 28 (10), 959-962, 2004.
20. Chang Y., Chen T. L., WU G. J., Hsiao G., Shen M. Y., Lin C. H., Sheu J. R., Mechanisms involved in the antiplatelet activity of ketamine in human platelets, BIOMED. SCI., 11, 764-772, 2004.
21. Takenaka I., Ogata M., Koga K., Matsumoto T., Shigematsu A. Ketamine suppresses endotoxin-induced tumor necrosis factor alpha production in mices, ANESTHESIOLOGY, 80, 402-408, 1994.
22. Kawasaki T., Ogata M., Kawasaki F., Ogata J., Inoue Y., Shigematsu A., Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro, ANESTH. ANALG., 89, 665-9, 1999.
23. Larsen B., Hoff G., Wihlhem W., Buchinger H., Wanner G., Bauer M., Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood, ANESTHESIOLOGY, 89, 1218-1227, 1998.
24. Taniguchi T., Kanakura H., Takemoto Y, Kidani Y., Yamamoto K., Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats, TOHOKU J. EXP. MED., 200, 85-92, 2003.
25. Kawasaki C., Kawasaki T., Ogata M., Nandate K., Shigematsu A., Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood, NEUROANESTH. AND INTENS. CARE, 48 (8), 819-823, 2001.
26. Taniguchi T., Shibata K., Yamamoto K., Ketamine inhibits endotoxin-induced shock in rats, ANESTHESIOLOGY, 95, 928-932, 2001.
27. Roytblat L., Talmor D., Rachinsky M., Greemberg L., Pekar A., Appelbaum A., Gurman G., Shapira Y., Duvdenani A. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass, ANESTH. ANALG., 87, 266-71, 1998.
28. Bartoc C., Frumento R., Jalbout M., Bennett-Guerrero E., Du E., Nishanian E., A randomised, double-blind , placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patient, J. CARDIOTHOR. VASC. ANESTH., 20 (2), 217-222, 2006.
29. Zeyneloglu P., Donmez A., Bilezikci B., Mercan S., Effects of ketamine on serum and tracheobronchial aspirate interleukin-6 levels in infants undergoing cardiac surgery, J. CARDIOTHOR. VASC. ANESTH., 19 (3), 329-333, 2005.
30. Sakai T., Takashi I., Whitten C. W., Giesecke A. H., Lipton J. M., Ketamine suppresses endotoxin-induced NF-κB expression. CAN. J. ANESTH., 47 (10), 1019-1024, 2000.
31. Sun J., Wang D., Liu H., Xu J. G., Ketamine suppresses endotoxin-induced NF-κB activation and cytokines production in the intestine, ACTA. ANAESTH. SCAND., 48, 317-321, 2004.
32. Zahler S., Heindl B., Becker B. F., Ketamine does not inhibit inflammatory responses of cultured human endothelial cells but reduces chemotactic activation of neutrophils, ACTA ANAESTHESIOL. SCAND., 43, 1011-1016, 1999.
33. van der Poll T., Coyle S. M., Barbosa K., Braxton C. C., Lowry S. F., Epinephrine inhibits Tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia, J. CLIN. INVEST., 97 (3), 713-9, 1996.
34. van der Poll T., Jansen J., Endert E., Sauerwein H. P., van Deventer S. J., Noradrenaline inhibits LPS-induced tnf-α and IL-6 production in human blood, INFECT. AND IMM., 62 (5), 2046-2050, 1994.
35. Mc Callion K., Harkin D.W., Gardiner K. R., Role of adenosine in immunomodulation : Review of the literature, CRIT. CARE MED., 32 (1), 273-277, 2004.
36. Rivkin I., Rosenblatt J., Becker E. L., The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbits peritoneal neutrophils, J. IMMUN., 115 (4), 1126-1134, 1975.
37. Cadieux J. S., Leclerc P., St-Onge M., Dussault A. A., Laflamme C., Picard S., Ledent C., Pouliot M. Potentiation of neutrophil cyclooxygenase-2 by adenosine : an early inflammation signal, JOURN. CELL. SCI., 118, 1437-1447, 2005.
38. Pouliot M., Fiset M.E., Massé M., Naccache P., Borgeat P., Adenosine up-regulates cyclooxygenase-2 in human granulocytes : impact on the balance of eicosanoid generation, J. IMMUN., 169, 5279-5286, 2002.
39. McColl S. R., St-Onge M., Dussault A. A., Laflamme C., Bouchard L., Boulanger J., Pouliot M., Immunomodulatory impact of the A2a adenosine receptor on profile of chemokines produced by neutrophils, FASEB JOURNAL, (nov) : 1-19, 2005.
40. Mazar J., Rogachev B., Shaked G., Ziv N. Y., Cziger D., Chaimovitz C., Zlotnik M., Mukmenev I., Byk G., Douvdevani A. Involvement of adenosine in the anti-inflammatory action of ketamine, ANESTHESIOLOGY, 102, 1174-81, 2005.
41. Hill G. E., Anderson J. L., Lyden E. R., Ketamine inhibits the proinflammatory cytokin-induced reduction of cardiac intracellular Adenosine accumulation, ANESTH. ANALG., 87, 1015-9, 1998.
42. Gilroy D. W., Colville-Nash P. R., Chivers W. J., Paul-Clarck M. J., Willoughby D. A., Inducible cyclooxygenase may have anti-inflammatory properties. NATURE MED., 5 (6), 698-701, 1999.
43. Poligone B., Baldwin A. S., Positive and Negative regulation of NFKB by COX-2, JOURN. BIO. CHEM., 276 (42), 38658-64, 2001.
44. Shimaoka M., Iida T., Ohara A., Taenaka N., Mashimo T., Honda T., Yoshiva I., Ketamine inhibits nitric oxide production in mouse-activated macrophage-like cells, BR. J. ANESTH., 77, 238-242, 1996.
45. Li C. Y., Chou T., Wong C. S., Ho S. T., Wu C. C., Yen M. H., Ding Y. A. Ketamine inhibits nitric oxide synthase in lipopolysaccharide-treated rat alveolar macrophages, CAN. J. ANESTH., 44 (9), 989-995, 1997.
46. Kelleher Z. T., Matsumoto A., Stamler J. S., Marshall H. E., NOS2 regulation of NF-κB by s-nitrosylation of p65, JOURN. BIOCHEM., august 24, 2007.
47. Kim F., Huri D. A., Snyder S. H., Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxxygenase-2, SCIENCE, 310, 1966-70, 2005.
48. Van Berkel B. N. M., Oranje B., van Ree J. M., Verbaten M. N., Kahn R. S., The effect of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects, PSYCHOPHARMACOLOGY, 137, 271-28, 1998.
49. Hergovich N., Singer E., Agneter E., Eichler H. G., Graselli U., Simhandl C., Jilma B., Comparision of the effects of ketamine and memantine on prolactin and cortisol release in men : a randomized, double-blind placebo-controlled trial, NEUROPSYCHOPHARMACOLOGY, 24 (5), 590-593, 2001.
50. Damianopoulos E. N., Carey R. J., Evidence for NMDA receptor mediation of cocaine induced corticosterone release and cocaine conditioned stimulant effect, BEHAV. BRAIN RES., 68, 219-228, 1995.
51. Rofael H. Z., Turkall R. M., Abdel-Rahman M. S., Immunomodulation by cocaine and ketamine in postnatal rats, TOXICOLOGY, 188, 101-104, 2003.
52. Ulloa L., The vagus nerve and the nicotinic anti-inflammatory pathway, NATURE REVIEWS, 4, 673-684, 2005. (Pubitemid 41149761)
53. Machado B. H., Neurotransmission of the cardiovascular reflexes in the Nucleus Tractus Solitarii of awake cat, ANN. N.Y. ACAD. SCI., 940, 179-96, 2001.
54. Jin Y. H., Bailey T. W., Doyle M. W., Li B. Y., Chang K. S. K., Schild J. H., Mendelowitz D., Andresen M. C., Ketamine differentially blocks sensory afferent synaptic transmission in medial Tractus Solitarius, ANESTHESIOLOGY, 98, 121-132, 2003.
55. Hayashi H., Dikkes P., Soriano G., Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain, PAEDIATRIC ANESTH., 12, 770-774, 2002.
56. Scallet A. C., Schmued L. C., Slikker W., Gunberg N., Faustino P. J., Davis H., Lester D., Pine P. S., Sistare F., Hanig J. P., Developmental neurotoxicity of ketamine, TOXICOL. SCIENCES, 81, 364-370, 2004.
57. Rudin M., Ben-Abraham R., Gazit V., Tendier Y., Tashlylov V., Katz Y., Single-dose ketamine administration induces apoptosis in neonatal mouse brain, J. BASIC CLIN. PHYSIOL. PHARMACOL., 16 (4), 231-43, 2005.
58. Perl M., Chung C. S., Ayala A., Apoptosis, CRIT. CARE MED., 33 (12), s526-528, 2005.
59. Muenzer J. T., Davis C. G., Schmidt R. E., Dunne W. M., Coopersmith C. M., Hotckiss R. S., Characterization and modulation of the immunosuppressive phase of sepsis, INFECT. AND IMMUNITY, 78 (4), 1582-1592, 2010.
60. Koga K., Ogata M., Takenaka I., Matsumoto T., Shigematzu A., Ketamine suppresses tnf-alpha activity and mortality in carrageenan-sensitized endotoxin shock model, CIRC. SHOCK., 44 (3), 160-8, 1994.
61. Shaked G., Czeiger D., Dukhno O., Levy I., Artru A. A., Shapira Y, Douvdevani A., Ketamine improves survival and suppresses IL-6 and TNf alpha production in a model of Gram-negative bacterial sepsis in rats, RESUSCITATION, 62, 237-242, 2004.
62. Gurfinkel R., Czeiger D., Douvdevani A., Shapira Y., Artru A. A., Sufaro Y., Mazar J., Shaked G., Ketamine improves survival in burn injury followed by sepsis in rats, ANESTH. ANALG., 103 (2), 392-402, 2006.
63. Neder Meyer T., Lazaro da Silva A., Ketamine reduces mortality of severely burnt rats, when compared to midazolam plus fentanyl, BURNS, 30, 425-430, 2004.
64. Taniguchi T., Takemoto Y., Kanakura H., Yamamoto K., The dose related effect of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats, ANESTH. ANALG., 97 (6), 1769-72, 2003.
65. Erden I.A., Pamuk A. G., Akinci S. B., Koseoglu A., Aypar U., Comparison of two ketamine-propofol dosing regimens for sedation during interventional radiology procedures, MINERV. ANEST., 76 (4), 260-265, 2010.